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• Ovarian cancer survivors who live for 10 or more years comprise a heterogeneous patient population with and without recurrent disease.
• Long-term survivors may have suboptimal cytoreduction or short platinum free intervals.
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Available online 11 March 2016Objective.High-grade serous carcinoma (HGSC) generally presents at an advanced stagewith poor long-term
(LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years.
Methods. A multi-center research consortium was established between ﬁve participating academic centers.
Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at
least ten years of follow up. Non-serous, borderline tumors and low-grade serous subtypes were excluded.
Results. The 203 identiﬁed LT ten-year survivors with HGSC were diagnosed at a median age of 57 years
(range 37–84 years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who
underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a
median follow up of 144 months, 88 (46.8%) patients did not develop recurrent disease after initial treatment.
Unexpected ﬁndings from this survey of LT survivors includes 14% of patients having had suboptimal
cytoreduction, 11% of patients having an initial platinum free interval of b12 months, and nearly 53% of patients
having recurrent disease, yet still surviving more than ten years after diagnosis.
Conclusions. LT survivors of HGSCof the ovary generally have favorable clinical features including optimal sur-
gical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent dis-
ease, howevermany remained disease free formore than 10 years. Futureworkwill compare the clinical features
of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Ovarian cancer has extensive heterogeneitywithin and between his-
tologic subtypes [1]. High-grade serous carcinoma is the most aggres-
sive subtype and accounts for the majority of advanced stage cases [2].
Ten-year survival for all ovarian cancer is approximately 30–40% ac-
cording to the SEER registry and other studies [3,4]. Long-term (LT) sur-
vival of women with high-grade serous carcinoma (HGSC) is low and
often associated with completely resected disease (no gross residual).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographic and clinical characteristics of long-term survivors
Na %
Age at diagnosis (years)
Median (range) 57 (37–84)
FIGO stage
I 7 3.5
II 9 4.4
III 164 80.8
IV 23 11.3
Grade
High 203 100
Histology
Serous 203 100
BRCA mutations
BRCA1 22 27.8
BRCA2 21 26.6
None 36 45.6
Residual disease
None 76 46.6
≤1 cm 61 37.4
N1 cm 26 16.0
Neoadjuvant therapy
No 184 92.9
Yes 14 7.1
Intraperitoneal therapy
No 145 79.2
Yes 38 20.8
Number of recurrences
0 88 46.6
1 21 11.2
2 19 10.1
N2 60 31.9
Platinum-free interval
b6 months 5 3.6
6–12 months 11 7.9
N12 months 124 88.6
FIGO, International Federation of Gynecology and Obstetrics.
a Numbers do not sum to the total for some variables due to missing values.
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HGSC beyond the current FIGO staging system, most have limited
value for patients with advanced stage disease [5,6]. Nonetheless, the
use of intraperitoneal therapy in patients with microscopic and small
volume residual disease after cytoreductive surgery has been associated
with long-term survival [7]. Nomograms have potential superiority over
traditional staging systems to predict individual probabilities of survival
[8,9]. Many studies have demonstrated thatmolecularmarkersmay im-
prove outcome prediction alone or in combination with clinical vari-
ables, however, none have been sufﬁciently robust to incorporate into
clinical practice to date [10–13]. Although many recently developed re-
sources are tremendously valuable for studying HGSC, in general, they
contain few LT survivors and those that are included often lack detailed
clinical and pathologic data [14]. The goal of this pilot report is to de-
scribe clinical variables, alone or in combination, that are found
among ten year survivors of HGSC with the overall goal of identifying
approaches for improving the outcomeof patientswith shorter survival.
2. Methods
A multi-center research consortium was established between ﬁve
participating academic centers: Memorial Sloan Kettering Cancer Cen-
ter, MD Anderson Cancer Center, Cedars-Sinai Medical Center, Stephen-
son Oklahoma Cancer Center at the University of Oklahoma, and
University of Iowa. IRB approval was obtained locally at each center.
Study criteria were established that included patients with a diagnosis
of high-grade serous ovarian, fallopian tube, or peritoneal carcinoma
with at least ten years of follow up from the date of initial diagnosis to
the date of death or last follow-up. All stages of cancer were permitted.
Diagnosis dates for patients in this study range from 1979 to 2005. Non-
serous, borderline tumors and low-grade serous subtypes were exclud-
ed in addition to any patients with insufﬁcient follow up data. Grade 2
tumors were excluded unless they were re-reviewed and met contem-
porary criteria for high-grade serous carcinoma. Clinical and disease
characteristics, including age at diagnosis, stage, residual disease after
primary surgery, treatment history, recurrence history, and results of
BRCA1 and BRCA2 germline genetic testing were collected frommedical
records. Major components (primary surgery and/or adjuvant chemo-
therapy) of initial treatment were performed at one of the ﬁve partici-
pating consortium centers. Cytoreductive surgery was characterized as
optimal if there was ≤1 cm of residual disease and suboptimal if
N1 cm of disease remained at the end of the surgical procedure. Consult
cases or other cases referred after the completion of initial therapywere
excluded. Data are reported in a descriptive fashion with summary sta-
tistics provided, as appropriate. An overall survival analysis using the
method of Kaplan and Meier was performed using the time from diag-
nosis to last follow-up for patients who did not recur and the landmark
event of recurrence to deﬁne the start of the overall survival interval for
patients who had recurred. Statistical analysis and visualization was
performed using R (http://www.R-project.org).
3. Results
3.1. Patient characteristics
Across the ﬁve centers, 203 patients were identiﬁed as LT ten-year
survivors and included in this study. Demographic and clinical charac-
teristics of the study group are shown in the Table 1. All patients were
diagnosed with high-grade serous carcinoma of the ovary, fallopian
tube, or peritoneum at their respective institution. The median age of
patients was 57 years (range 37–84 years). Twenty-eight patients
(13.8%) were older than 70 years at the time of diagnosis. The majority
of patients were white (88.7%) and diagnosed with stage IIIC (72.4%)
disease at presentation.
Of the 23 patients with stage IV disease, 12 (52%) had available data
that indicated 5 had stage IV disease based on pleural effusion only. Ofthe seven patients with distant metastases or solid organ involvement,
3 patients had parenchymal liver metastases, two patients had
supraclavicular nodal involvement and one patient each had pleural
metastasis or abdominal wall involvement. All three patients with
liver metastases remained progression free for more than 10 years
and have not developed recurrence. Available data for 157 (96%) of
164 stage III patients indicate that 26 (17%) had stage III disease due
to lymph node only disease.
Of the 198 patients with available treatment information, 92.9%
underwent primary cytoreductive surgery and 7.1% received neoadju-
vant chemotherapy prior to interval cytoreductive surgery. Of those
who underwent primary cytoreductive surgery, optimal cytoreduction,
deﬁned as residual disease of less than or equal to 1 cm inmaximum di-
ameter, was achieved in 143 (85.6%) patients. A complete gross resec-
tion to no macroscopic residual disease was achieved in 70 (47.0%)
patients. Ascites was present at the time of surgery in 103 (70.5%) pa-
tients. All but one patient (99.5%) received a platinum agent as part of
their adjuvant or neoadjuvant treatment regimens. Intraperitoneal che-
motherapywas given to 38 (20.8%) patients,withmost of these patients
receiving IP treatment as part of consolidation therapy.
3.2. Treatment outcome
After a median follow up of 144 months, 88 (46.8%) patients did not
develop recurrent disease after initial treatment. This groupwas charac-
terized by a high optimal cytoreduction rate (93%, 78/84) and a low rate
of neoadjuvant chemotherapy (6%, 5/88). Themajority of patients in the
entire cohort were reported to be platinum sensitive (96.4%) with a
platinum-free interval of N12months for 124 (88.6%) patients. The me-
dian progression-free survival (PFS) of the entire cohort was
147 months. Twenty-one (11.2%) patients had one recurrence during
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fered from more than two recurrences, with 13 patients having more
than 10 reported recurrences. In the group of patients who experienced
one recurrence, eight (44%) of 18 with available data underwent sec-
ondary cytoreduction and 16 (89%) received a platinum agent. The
two patients who did not receive a platinum agent for their ﬁrst recur-
rence received single-agent paclitaxel or cytoreduction alone. Only 19%
(n = 4) of the 21 patients with a single recurrence recurred within
24 months of diagnosis. BRCA1 and BRCA2 germline mutation status
was known for 79 (38.9%) patients and of those tested 43 (54.4%)
were found to carry a deleterious mutation. There were no identiﬁable
survival differences between the subsets of patients with or without
BRCA1 and BRCA2 germline mutations.
Data regarding disease-free intervals after the ﬁrst recurrence were
not collected as part of this pilot study. Therefore, a landmark analysis
was performed to examine the survival pattern after ﬁrst recurrence.
For patients with recurrence, the landmark time of ﬁrst recurrence
was used as the start of the survival interval and date of diagnosis was
used as the start of the survival interval for patients without recurrence.
This analysis demonstrated that some patients recurred early and con-
tinued to have LT survival, whereas other patients recurred late and
had shorter survival after recurrence (Fig. 1). The survival curve sug-
gests that both situations are common and equally represented in the
cohort.
Twenty-four patients (13.4%) of 179 patients with available data
participated in a clinical trial as part of initial adjuvant therapy. Four pa-
tients who received targeted therapy with cetuximab including 3 with
stage IIIC disease, and one had stage IV disease. All were BRCA carriers
(two with BRCA1mutations and two with BRCA2mutations). Three pa-
tients developed recurrence once between 17 and 39months after diag-
nosis and were treated with secondary cytoreduction followed by
additional platinum-based therapy. The one stage IV patient never re-
curred. All four were without disease at a median overall survival of
122 months (range 121–126 months).Fig. 1. Landmark survival analysis. Patientswith recurrence have a survival curvewith two
component slopes suggesting both early and late events. Since this is a landmark analysis
from time of recurrence in a cohort that has 10 or more year survival, the early events are
late recurrence and the later events are early recurrence in patients who have a true
overall survival of at least 10 years.3.3. Unusual responders
Unexpected ﬁndings from this survey of LT survivors includes 15% of
patients having suboptimal cytoreduction at the time of primary surgi-
cal resection, 11% of patients having a platinum free interval of b-
12 months, and 53% of patients having recurrent disease, yet still
surviving more than ten years after diagnosis. Other unusual features
of LT survivors include four patients with suboptimal cytoreduction
and a platinum-free interval (PFI) of b12 months. All were diagnosed
with stage IIIC disease and none of them participated in a clinical trial
as part of their adjuvant therapy. Within the subset of patients who re-
ceived neoadjuvant chemotherapy, 50% survived 10 or more years
without recurrence, a proportion similar to the overall studypopulation.
There were eight patients with stage IV disease who did not experi-
ence any recurrence of their disease after initial treatment. The median
OS of these survivors was 131 months (range 122–204 months). All
eight women had an optimal debulking with b1 cm of residual disease,
ﬁve at primary debulking and three at interval debulking surgery after
neoadjuvant chemotherapy. Those that received neoadjuvant chemo-
therapy all received carboplatin and paclitaxel, ranging from three to
six cycles. Two women in this group had BRCA1 mutations; one had
tested negative for a BRCA1 or BRCA2mutation and the remaining ﬁve
patients were not tested. Thirty patients had a disease-free interval of
b2 years. The median age at diagnosis was 54. The majority (25, 83%)
had stage III disease. Five patients remained without disease following
their ﬁrst recurrence and the others suffered from additional
recurrences.
Of the patients undergoing primary surgical resection, 23 (15%) of
151 patients with available data had suboptimal cytoreduction and
these patients had amedian PFS of 76months. The patients with subop-
timal tumor resectionweremore likely to receive consolidation therapy
after completing primary chemotherapy. Consolidation data was avail-
able for 139 (92%) of the 151 patients that underwent primary surgical
resectionwith a known size of residual disease. Of these patients, 72% of
the 18 patients who had suboptimal cytoreduction received consolida-
tion therapy compared to only 31% of the 121 patients having optimal
cytoreduction (P = 0.001, Fisher's exact test).
4. Discussion
In this study, we identify demographic, pathologic, surgical, and
treatment-related clinical factors associated with LT survival in HGSC.
LT survivors exist both with andwithoutmultiple recurrences. They ap-
pear to have a slightly younger age than the average patient with ad-
vanced stage HGSC and are likely to have had optimal surgical
cytoreduction, deﬁned at the time of this study as b1 cm of residual dis-
ease. There are intrinsic biologic factors associatedwith platinum sensi-
tivity that are generally associated with long-term survival, but a
surprising yet small fraction of patients who had either suboptimal
cytoreduction or primary platinum resistance achieved LT survival.
The study is descriptive in nature to highlight the characteristics of pa-
tients with HGSC who survive 10 or more years after diagnosis. Future
studies will compare this group of patients with others who have
HGSC and are shorter-term survivors. We will also examine genetic
and reproductive factors in future work, including the role of germline
mutations in BRCA1, BRCA2 and other functionally-related genes.
The low use of neoadjuvant chemotherapymay be directly associat-
ed with long-term survival or may be a reﬂection of the time period
under study, which is by deﬁnition at least 10 years ago. Furthermore,
the complete gross resection rate of nearly 50% may be unexpectedly
high during a time period when the goals of cytoreductive surgery
were generally deﬁned no more than 1 cm of residual disease in maxi-
mal dimension.
Though studies have shown that survival of advanced stage HGSC
patients is poor, there is a dearth of collective data on 10-year survivors
of HGSC with sufﬁcient clinical annotations to determine which
263F. Dao et al. / Gynecologic Oncology 141 (2016) 260–263modiﬁable and predictive characteristics are reliably associated with
outcome. The few studies that have been conducted generally examined
multiple histologic types together. For example, in a study of mixed his-
tologic subtypes from Sweden, age, stage, residual disease and post-
operative CA-125 were all associated with LT survival [3]. A SEER regis-
try study found that advanced stage patients and those who did not re-
ceive primary surgical resection had worse LT outcomes [4]. A recent
study reported a 31% 10-year survival of mixed histologic subtypes
from a state registry [15]. The authors reported that 16% of patients
with advanced stage HGSC survived 10 years, but there was no indica-
tion of treatment regimens, patterns of recurrence or other clinical fea-
tures of their disease provided.
The data from this pilot study indicate that long-term survivors of
HGSC frommajor academicmedical centers have high surgical resection
to no visible disease and there are many patients without any episodes
of disease recurrence among 10-year survivors. We do not know how
these and other variables compare to shorter-term survivors and future
workwill compare these 10-year survivors to shorter-termovarian can-
cer survivors.
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